A year after anti-GM-CSF monoclonal antibody KB003 failed in a phase II severe asthma study, Kalobios Pharmaceuticals Inc. once again found itself shifting priorities on news of the phase II miss for its second lead product, anti-PcrV monoclonal antibody fragment KB001-A, in treating Pseudomonas aeruginosa (Pa) lung infections in cystic fibrosis (CF) patients.